---
title: "Orthoptics in the United States: Handoff Summary"
date: "2026-06-26"
status: "Condensed synthesis of three research memos"
source_documents:
  - "orthoptics-burden-funnel.md"
  - "orthoptics-in-usa.md"
  - "pediatric-eye-care-CHLA-USC.md"
---

# Orthoptics in the United States: Handoff Summary

## Purpose

This document condenses three research memos into one stand-alone brief covering:

1. the national burden of orthoptics-relevant disease and the screening-to-treatment funnel;
2. the size, function, and limitations of the U.S. orthoptic workforce; and
3. Los Angeles County and Children’s Hospital Los Angeles (CHLA)/USC as a concrete regional case.

The source research distinguishes between **measured**, **estimated**, **modeled**, and **low-confidence or inferred** findings. That distinction should be preserved in any downstream presentation. Full primary-source citations remain in the three source documents listed at the end.

## Executive summary

Orthoptics-relevant disorders are common enough to create population-scale demand. U.S. population-based studies place preschool manifest strabismus at approximately **2.5%–2.6%** and amblyopia at approximately **1.8%–2.6%**, depending on the cohort. Applied to the current preschool population, those rates imply roughly **half a million children with strabismus**, **0.4–0.6 million with amblyopia**, and approximately **1.1 million with amblyopia risk factors**. Commercial-claims data across childhood also suggest diagnosed strabismus and amblyopia populations in the millions when extrapolated nationally, although those extrapolations are less secure than the preschool prevalence studies.

The main system failure occurs before effective treatment. Screening at age three has been reported at only about **40%**, and community follow-up after a failed preschool screen has often been approximately **59%**. In a nationally representative school-age pathway, **61%** were screened within two years, **30%** of those screened were referred, and **92%** of those referred established specialty care—equivalent to about **16.8% of all school-age children** moving through that specific screened-to-referred-to-seen pathway. These figures come from different populations and should not be presented as one unified national cohort.

Treatment efficacy is not the central uncertainty. Trials show that amblyopia and convergence insufficiency often improve when children reach appropriate care and adhere to treatment. The more persistent operational problems are incomplete screening, referral leakage, appointment access, insurance barriers, spectacle access, treatment adherence, and recurrence.

The profession positioned to help manage these bottlenecks is extremely small. The best public proxy identified for the U.S. certified-orthoptist community is **440 registered AACO members in 2022**, not a verified count of active practitioners. Official pages conflict between **17 and 18 U.S. training programs**, and publicly posted intake data suggest national output is probably only in the **teens of graduates per year**. The profession therefore appears undersupplied, but the exact shortage cannot be quantified from current public data.

Orthoptists create value through high-skill delegation: standardized sensorimotor measurement, amblyopia management, prism and diplopia workups, pre- and postoperative strabismus assessment, selected binocular-vision therapy, and protocolized follow-up under ophthalmologist supervision. This is not generic technician substitution. Measurement variability can alter diagnosis, surgical dosing, and interpretation of postoperative change. An older U.S. manpower-survey claim associated one full-time orthoptist with up to **50% greater patient volume** and **28% greater surgical volume**, but that estimate is dated and should be treated as suggestive rather than definitive. Contemporary international service models provide stronger evidence that orthoptist-led pathways can safely preserve ophthalmologist time and reduce visit time or labor cost in selected protocols.

Los Angeles County demonstrates how disease burden, access inequality, and specialist concentration converge. The county has approximately **1.94 million children under 18**. Applying local MEPEDS prevalence data to current age-band estimates produces approximately **12,700–13,300 preschool children with strabismus** and **5,100–8,900 with amblyopia**, plus much larger pools with hyperopia and astigmatism. Nearly half of county children are covered by Medi-Cal, with coverage exceeding **60%–70%** in several high-burden service-planning areas.

CHLA’s Vision Center is a major regional capacity node: approximately **17,000 annual visits**, more than **1,400 ophthalmic surgeries**, a team of more than **20 ophthalmologists, optometrists, and orthoptists**, broad pediatric ophthalmic subspecialty coverage, and a formal USC/Keck training affiliation. Orthoptists are publicly described as integrated into precise diagnosis and eye-movement/strabismus management. The absence of CHLA would not simply redistribute the same care without consequence; the likely result would be longer waits, more travel, fragmented workups, and increased referral loss, especially for Medi-Cal-insured and medically complex children. The exact magnitude of that counterfactual remains modeled because CHLA does not publicly report Vision Center payer mix, orthoptist full-time equivalents, or orthoptic-specific visit volume.

## The argument in one chain

1. **The underlying clinical burden is large.** Strabismus, amblyopia, refractive risk factors, diplopia, and adult-onset ocular-motility disorders collectively generate substantial pediatric and adult demand.
2. **The care pathway loses patients early.** Screening and referral completion are less reliable than treatment efficacy once specialty care is established.
3. **Orthoptists work at high-value bottlenecks.** Their role combines precise measurement, longitudinal management, protocolized care, and physician extension.
4. **The U.S. workforce is very small.** The available evidence points to hundreds of practitioners and only a small annual training pipeline.
5. **Access is geographically and financially uneven.** Pediatric eye-care supply is concentrated in metropolitan and higher-income areas, while Medicaid access and wait times are worse.
6. **CHLA is a concrete example of orthoptics embedded in a high-throughput hub.** Its scale, breadth, safety-net context, and USC affiliation make it difficult to replace with fragmented community capacity.
7. **The strategic gap is measurement.** The evidence strongly supports need and plausible value, but not a precise modern U.S. return-on-investment, workforce deficit, or optimal staffing ratio.

## Key numbers to carry forward

| Domain | Figure | Interpretation | Evidence status |
|---|---:|---|---|
| Preschool strabismus prevalence | **2.5%–2.6%** | Approximately 1 in 40 preschool children has manifest strabismus in major U.S. population-based cohorts. | Measured |
| Preschool amblyopia prevalence | **1.8%–2.6%** | Amblyopia affects a smaller but still population-scale share of preschool children. | Measured |
| Preschool amblyopia risk factors | **5.0%** | The upstream at-risk population is substantially larger than the diagnosed amblyopia population. | Measured |
| Estimated U.S. preschool burden | **~0.56M strabismus; ~0.40M–0.58M amblyopia; ~1.12M risk factors** | Current-population extrapolations show the scale of potential demand. | Estimated |
| Commercial-claims prevalence | **3.2% strabismus; 1.5% amblyopia** | Diagnosed disease across all of childhood is substantial, but commercial claims are not nationally representative of all children. | Measured, with limited generalizability |
| Screening at age three | **~40%** | The pipeline begins with low coverage during a time-sensitive treatment window. | Measured |
| Preschool follow-up after failed screen | **~59%** | Roughly four in ten referred preschoolers may fail to complete the next step in community pathways. | Measured/local |
| School-age pathway | **61% screened → 30% referred → 92% seen** | Approximately **16.8%** of all school-age children moved through this particular screened-to-referred-to-seen pathway. | Measured plus arithmetic estimate |
| Spectacle adherence | **71%** | Even after treatment is prescribed, real-world wear is incomplete. | Measured/local |
| Patching adherence | **Often <50%** | Treatment failure can reflect implementation and adherence, not only biological nonresponse. | Low-confidence synthesis |
| Amblyopia recurrence | **~25% within one year** | Successful treatment still requires continued follow-up. | Measured |
| U.S. certified-orthoptist proxy | **440 AACO members** | Best public proxy for profession size; not an active-workforce census. | Estimated proxy |
| U.S. training programs | **17 or 18** | Official public sources conflict; published seat counts are commonly one trainee per year or less. | Measured, internally inconsistent |
| Estimated national training output | **Likely teens per year** | The pipeline is too small to expand the workforce rapidly. | Estimated |
| Pediatric ophthalmologists | **~1,056 nationally; ~90% of counties without one** | The physician workforce orthoptists commonly support is itself geographically sparse. | Measured |
| LA County children under 18 | **~1.94M** | Even low prevalence produces large absolute caseloads. | Estimated from Census measures |
| LA preschool strabismus | **~12,700–13,300** | Local burden modeled from MEPEDS prevalence and current county age bands. | Estimated |
| LA preschool amblyopia | **~5,100–8,900** | Several thousand preschool children likely have amblyopia countywide. | Estimated |
| LA County child Medi-Cal coverage | **47.7%** | Pediatric eye care is materially a safety-net issue; selected areas exceed 60%–70%. | Measured |
| CHLA Vision Center scale | **~17,000 visits; >1,400 surgeries/year** | CHLA is a high-throughput regional referral and surgical hub. | Measured from CHLA materials |
| CHLA Vision Center team | **>20 ophthalmologists, optometrists, and orthoptists** | Orthoptics is embedded within a broad pediatric ophthalmic subspecialty team. | Measured from CHLA materials |

## National burden and treatment funnel

### The burden is broader than diagnosed amblyopia alone

The most useful way to understand national need is as three overlapping layers:

- **Upstream risk:** approximately 5% of preschool children have amblyopia risk factors, and a similar share may meet spectacle-prescribing criteria. This is the prevention-sensitive population in which screening, refraction, spectacle provision, and follow-up can prevent or reduce later visual loss.
- **Established pediatric disease:** strabismus and amblyopia affect hundreds of thousands of preschool children and potentially millions across the full pediatric age range.
- **Adult orthoptic demand:** adult-onset strabismus, diplopia, convergence insufficiency, and acquired nystagmus create an additional service burden. One population-based incidence estimate extrapolates to roughly **145,000 new adult-onset strabismus cases per year**, while national visit data identified approximately **850,000 diplopia-related ambulatory and emergency visits annually**. These are estimates or visit counts, not a unified patient census.

This structure matters because orthoptics is sometimes framed as narrowly pediatric or limited to postoperative strabismus measurement. The evidence instead supports a broader role across pediatric ophthalmology, adult strabismus, binocular-vision disorders, and selected neuro-ophthalmic pathways.

### The funnel is fragmented

There is no single U.S. dataset that follows the same child from screening through referral, examination, diagnosis, treatment initiation, adherence, resolution, and recurrence. The national funnel must therefore be assembled from multiple studies with different ages, settings, definitions, and denominators.

The assembled evidence still identifies a consistent pattern: the largest losses occur **before diagnosis and sustained treatment**. Children are missed at screening, fail to complete referral, encounter insurance or geographic barriers, wait for appointments, fail to obtain spectacles, or do not adhere to patching or other treatment. By contrast, randomized trials show meaningful treatment response once children receive appropriate care.

### Treatment works, but it is not self-executing

Relevant efficacy findings include:

- atropine and patching produced similar improvement by six months in children younger than seven with moderate amblyopia;
- among children aged 7 to under 13, active amblyopia treatment produced a **53% responder rate** versus **25%** with optical correction alone;
- office-based vergence/accommodative therapy with home reinforcement produced a **73% successful-or-improved rate** for symptomatic convergence insufficiency at 12 weeks, with most early responders remaining improved at one year; and
- amblyopia recurrence remains approximately **25%** in the first year after successful treatment.

The operational conclusion is that diagnosis, access, adherence, and follow-up determine how much of the trial efficacy is realized in routine care.

## U.S. orthoptic workforce and value proposition

### Workforce size and pipeline

The public evidence does not provide a current, audited count of actively practicing U.S. certified orthoptists. The strongest proxy is the 2022 survey denominator of **440 registered AACO members**. That number may include inactive, retired, nonclinical, or otherwise non-practicing members and should not be treated as a precise workforce census.

The training pathway is formal but very small:

- standard training is approximately **24 months**;
- current standards require at least **2,000 supervised clinical hours** and **1,250 patient encounters**;
- official pages disagree on whether there are **17 or 18** accredited U.S. programs; and
- publicly reported program intake is often one trainee per year, with at least one program accepting one trainee every two years.

The defensible conclusion is not an exact vacancy count. It is that the profession is in the low hundreds, the annual pipeline is probably in the teens, and visible placement and job-posting signals are more consistent with shortage than oversupply.

### Why orthoptic measurement matters

Orthoptists add value because ocular-alignment and binocular-vision measurements are clinically consequential and inherently variable. Repeatable prism-cover measurements, prism-adaptation testing, sensory evaluation, and standardized pre- and postoperative assessment can alter diagnosis, surgical dose, or interpretation of change.

The source research notes that only relatively large changes in prism-cover testing are confidently distinguishable from measurement variation, and a modeling study attributed approximately half of strabismus reoperations to the combined effects of measurement inaccuracy, strategy variation, and surgical imprecision. This does not mean orthoptists eliminate reoperation. It means skilled, standardized measurement is part of the causal chain that protects surgical decision quality.

### Capacity and efficiency

AOC and AAPOS materials describe orthoptists as physician extenders who can conduct sensorimotor examinations, manage selected follow-up pathways, support amblyopia treatment, conduct prism and diplopia workups, and perform reimbursable services under physician supervision.

The best quantified U.S. productivity claim—up to **50% higher patient volume** and **28% higher surgical volume** after adding a full-time orthoptist—comes from an older survey and is not readily auditable in modern public data. It should be presented as a hypothesis-generating benchmark, not a guaranteed staffing return.

More rigorous contemporary evidence comes from UK and Australian models. In selected neuro-ophthalmology, glaucoma, and NF1 screening pathways, orthoptist-led care showed high agreement with ophthalmologists, high patient satisfaction, and reductions in clinician time or labor cost. These studies demonstrate the mechanism of value—safe redistribution of stable, protocolized work—but do not establish a U.S.-specific financial return.

## Los Angeles County and the CHLA/USC case

### Local disease burden

MEPEDS remains the strongest local epidemiologic anchor because it was population-based, led by USC-affiliated investigators, and focused on the preschool disorders most relevant to orthoptics and pediatric ophthalmology.

Applied to current LA County age estimates, the study’s subgroup prevalence rates imply approximately:

- **12,700–13,300** preschool children with strabismus;
- **5,100–8,900** preschool children with amblyopia;
- **19,600–35,000** with preschool myopia;
- **110,000–143,000** with hyperopia; and
- **67,000–89,000** with astigmatism.

These categories overlap and should not be summed. They also do not all represent children who need surgery or direct orthoptic care. They define the upstream pool from which amblyopia, strabismus, spectacle, binocular-vision, and referral demand emerges.

MEPEDS is older and strongest for Hispanic/Latino and African American preschool cohorts. The local counts are therefore current-population models based on older measured prevalence, not direct 2026 county surveillance.

### Insurance and access

Approximately **47.7%** of LA County children are covered by Medi-Cal and **3.6%** are uninsured. Medi-Cal concentration is highly uneven: reported child coverage reaches **71.2%** in SPA 6 South and **60.7%** in SPA 4 Metro, versus **17.7%** in SPA 5 West.

The same higher-Medi-Cal areas report weaker general pediatric utilization and greater difficulty accessing care. National pediatric-eye evidence aligns with that pattern: Medicaid-insured children have lower appointment success, longer waits, and particularly limited access at ages 0–5. This is the worst point in the life course to encounter access delay because amblyopia treatment is time-sensitive.

### CHLA’s regional role

CHLA’s Vision Center reports approximately **17,000 annual visits** and more than **1,400 ophthalmic surgeries**, with broad pediatric subspecialty coverage and more than **20 ophthalmologists, optometrists, and orthoptists**. It is embedded in a large tertiary and quaternary children’s hospital capable of coordinating anesthesia, oncology, neurology, genetics, rehabilitation, and other complex pediatric needs.

The orthoptic role is explicit in CHLA’s public materials. Orthoptists are described as supporting precise diagnosis and working with ophthalmologists in eye-movement and strabismus measurement and management. That role likely improves examination consistency, supports surgical planning, and increases the number of patients ophthalmologists can evaluate and manage, although CHLA does not publicly report orthoptist-specific throughput or staffing.

The USC/Keck affiliation adds a training and academic layer: pediatric ophthalmology fellowship training, faculty recruitment, research infrastructure, and a direct connection to locally important epidemiology such as MEPEDS.

### Counterfactual without CHLA

The directly measured counterfactual burden is the service volume that would need to move elsewhere: approximately **17,000 visits and more than 1,400 surgeries per year**, including complex pediatric cases that cannot be fully absorbed by routine community practices.

A county-average payer assumption would imply approximately **8,100 Medi-Cal-linked visits** and **668 Medi-Cal-linked surgeries**, but those are modeled lower-bound estimates—not CHLA’s actual payer mix. CHLA may serve a higher safety-net share because it receives medically complex and tertiary referrals, but that inference is not publicly quantified.

The most defensible conclusion is qualitative: without CHLA, some patients would transfer to other academic centers or private practices, but redistribution would produce friction. Expected effects include longer waits, increased travel, fragmented workups, greater pressure on remaining pediatric specialists, and more referral leakage among Medicaid-insured and medically complex children.

## What the evidence supports

The combined evidence supports the following claims:

- Orthoptics-relevant disease creates substantial pediatric and adult demand in the United States.
- The most consequential system losses occur in screening coverage, referral completion, appointment access, treatment acquisition, adherence, and follow-up.
- Orthoptists occupy clinically meaningful tasks that can protect measurement quality and preserve ophthalmologist capacity.
- The U.S. orthoptic workforce and training pipeline are very small relative to the size of the burden and the pediatric ophthalmology access problem.
- Large multidisciplinary centers such as CHLA are important because they combine orthoptics, pediatric ophthalmology, surgery, subspecialty breadth, and complex-care infrastructure in one pathway.
- Better workforce and operations data are required before making precise staffing, return-on-investment, or national expansion claims.

## Claims that should not be overstated

Avoid presenting the following as established facts:

- **An exact current U.S. orthoptist headcount.** The 440-member figure is a proxy, not a verified active-practice census.
- **A precise national shortage number.** Shortage signals are strong, but unmet demand and vacancy totals have not been modeled publicly.
- **A guaranteed 50% patient-volume or 28% surgical-volume gain.** Those figures come from an older, low-auditability survey.
- **A complete national treatment funnel.** Funnel stages come from separate studies and populations.
- **Current direct LA County prevalence counts.** Local case counts are modeled from older MEPEDS prevalence and current Census denominators.
- **CHLA’s actual Medi-Cal payer mix or orthoptic volume.** Both remain unavailable in public division-level data.
- **A direct transfer of UK/Australian economics to U.S. practice.** International studies establish plausibility and mechanism, not a U.S. budget impact.
- **A quantified number of children who would go untreated without CHLA.** The counterfactual is structurally strong but not directly measured.

## Highest-value next data collection

For a stronger operational or funding case, the next work should focus on data that convert plausible value into measured local performance:

1. **U.S. workforce census:** active certification status, employment status, full-time equivalents, age, state, practice setting, retirement horizon, vacancies, and annual program output.
2. **CHLA orthoptics operations:** orthoptist headcount/FTE, visits or encounters supported, patient diagnoses, new-versus-follow-up mix, no-show rate, wait time, procedures supported, and proportion of strabismus surgery cases receiving orthoptic evaluation.
3. **Payer and access analysis:** Vision Center payer mix, authorization denial, referral-to-visit time, language needs, geography, and completion rates by Medi-Cal versus private insurance.
4. **Prospective throughput study:** ophthalmologist time, total visit time, patient volume, surgical scheduling, measurement repeatability, and cost before and after orthoptist staffing changes.
5. **Local care funnel:** screening result → referral → completed exam → diagnosis → treatment start → adherence → visual outcome → recurrence, linked at the patient level.
6. **Regional capacity map:** pediatric ophthalmologists, orthoptists, pediatric optometrists, insurer acceptance, new-patient wait, language access, and hospital-based surgical capability across LA County and adjacent referral regions.

## Reusable positioning paragraph

Orthoptics in the United States is a small and undermeasured profession working inside a large and leaky eye-care pathway. Strabismus, amblyopia, refractive risk factors, diplopia, and ocular-motility disorders create population-scale demand, but children are frequently lost before diagnosis through incomplete screening, failed referral, insurance barriers, and limited specialist access. Orthoptists address a high-value portion of that problem by providing standardized binocular-vision and alignment assessment, longitudinal amblyopia and strabismus management, and protocolized follow-up that preserves ophthalmologist capacity. Los Angeles County illustrates the need: thousands of preschool children are likely affected, nearly half of children rely on Medi-Cal, and CHLA’s Vision Center absorbs approximately 17,000 visits and more than 1,400 surgeries each year. The case for orthoptics is therefore strongest as a capacity, quality, and access strategy—not as an isolated technical role—but modern U.S. workforce and return-on-investment data remain the central evidence gap.

## Source documents

1. **United States Orthoptics Burden and Treatment Funnel** — `orthoptics-burden-funnel.md`
2. **Orthoptics in the United States** — `orthoptics-in-usa.md`
3. **Los Angeles County Pediatric Eye Care and the CHLA USC Orthoptics Ophthalmology Hub** — `pediatric-eye-care-CHLA-USC.md`

All primary-source citations and detailed stat tables are retained in those source documents.